Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.25.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2025
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended September 30, 

​

Nine-Month Periods Ended September 30, 

($ in thousands)

    

2025

    

2024

    

2025

    

2024

EmrosiTM

​

$

4,883

​

$

—

​

$

9,748

​

$

—

Qbrexza®

​

​

7,361

​

​

7,583

​

​

19,470

​

​

19,435

Accutane®

​

 

2,769

​

 

3,996

​

 

9,818

​

 

15,534

Foam franchise products (Amzeeq® & Zilxi®)

​

​

1,311

​

​

2,100

​

​

3,973

​

​

4,703

Other / legacy

​

​

701

​

​

950

​

​

2,164

​

​

2,842

Total product revenues

​

$

17,025

​

$

14,629

​

$

45,173

​

$

42,514

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended September 30,

​

Nine-Month Periods Ended September 30,

($ in thousands)

    

2025

    

2024

    

2025

    

2024

Cutia supply of Amzeeq

​

$

606

​

$

—

​

$

606

​

$

—

Total other revenues

​

$

606

​

$

—

​

$

606

​

$

—